Published on 28/07/2026

Managing Electronic Records in Computerized Systems According to Revised Schedule M

Why This Schedule M Topic Matters

Revised Schedule M emphasizes the importance of maintaining data integrity within electronic records that are part of computerized systems. As the pharmaceutical industry increasingly relies on technology for data management, understanding these expectations is vital for compliance with Good Manufacturing Practices (GMP) in India. Accurate electronic records not only serve regulatory requirements but also enhance operational efficiency and trust in pharmaceutical manufacturing processes.

Common Compliance Weakness

Many organizations struggle with compliance related to electronic records. Common weaknesses include:

• Lack of formalized procedures for managing electronic records.
• Inadequate access controls leading to unauthorized modifications.
• Failure to validate systems, resulting in unreliable data.
• Insufficient training of personnel on data integrity principles.
• Inconsistent backup protocols, risking data loss.

Better GMP / Schedule M Approach

A robust approach to managing electronic records involves:

• Establishing comprehensive standard operating procedures (SOPs) for electronic record management.
• Implementing stringent access control measures, defining roles and responsibilities clearly.
• Conducting regular training sessions focused on data integrity and Schedule M compliance.
• Utilizing validated systems that ensure data accuracy and reliability through appropriate checks.
• Documenting all changes and ensuring traceability in electronic records.

Risk-Based Control Considerations

A risk-based approach should be integrated into electronic record management by:

• Assessing risks associated with data handling and formulating controls based on impact and likelihood.
• Prioritizing validation efforts on systems that manage critical data.
• Continuously monitoring electronic systems for potential vulnerabilities.
• Adjusting protocols based on risk assessments and past CAPA outcomes.

Documentation, Training and CAPA Strategy

Effective documentation and training are integral to compliance:

• Maintain clear records of training sessions relating to electronic records governance.
• Use CAPA (Corrective and Preventive Actions) to address any compliance failures swiftly.
• Regularly review and update SOPs to reflect current practices and regulatory changes.

Inspection Relevance

During CDSCO inspections, the scrutiny of electronic records management can lead to critical findings. Inspectors will assess:

• The effectiveness of established procedures.
• The training and adherence levels of staff.
• How data integrity is maintained and documented.
• The audit trails available for changes made in electronic records.

Evidence and Effectiveness Check

Ensure evidence of compliance by incorporating:

• Regular audits of electronic record management processes.
• Documented reviews of SOP effectiveness findings.
• Scheduled assessments of training competency regarding data integrity.

QA Review Questions

Use the following questions for a thorough review of your electronic records management practices:

• Are all electronic records backed up according to a defined schedule?
• Is access to electronic records restricted and monitored?
• Are changes to electronic records logged with detailed audit trails?
• Is there a process for training new staff on electronic record compliance?
• Are there established procedures for addressing data integrity breaches?

Practical Example or Sample Wording

Consider this sample wording for an SOP addressing electronic records:

“All electronic records must be backed up daily and stored securely, with access limited to authorized personnel only. Changes made to these records will be tracked through detailed audit logs, ensuring full traceability of all alterations.”

Conclusion

Controlling electronic records for computerized systems under Revised Schedule M is pivotal for maintaining compliance, ensuring data integrity, and preparing for inspections. By addressing common compliance weaknesses and adopting a structured, risk-based approach, pharmaceutical organizations can foster a robust environment that meets both regulatory expectations and industry standards.